| Dr Christopher Libby, MD | |
|
1801 E Katella Ave Apt 3060, Anaheim, CA 92805-6658 | |
| (774) 644-4357 | |
| Not Available |
| Full Name | Dr Christopher Libby |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 7 Years |
| Location | 1801 E Katella Ave Apt 3060, Anaheim, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710411459 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cedars-sinai Medical Center | Los angeles, CA | Hospital |
| Huntington Memorial Hospital | Pasadena, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cedars-sinai Medical Center Pharmacy 3 | 0446169114 | 648 |
| Hmh Emergency Medical Group, Inc. | 7911800826 | 44 |
News Archive
Dysfunctional, unloved and seemingly of little use, these poor-cousin relatives of genes have lost their protein-coding abilities. They contain material not essential for an organism's survival and are the "last stop" for removal of genomic waste.
A rapid new diagnostic test developed by Sydney researchers will mean fewer tests and less trauma for cancer patients says Richard Christopherson, who has a Personal Chair in the School of Molecular and Microbial Biosciences in the Faculty of Science.
In an important test of one of the first drugs to target core symptoms of autism, researchers at Mount Sinai School of Medicine are undertaking a pilot clinical trial to evaluate insulin-like growth factor (IGF-1) in children who have SHANK3 deficiency (also known as 22q13 Deletion Syndrome or Phelan-McDermid Syndrome), a known cause of autism spectrum disorder (ASD).
Merck, known as MSD outside the United States and Canada, today announced final results from a Phase II clinical study, extending out to 240 weeks, of its integrase inhibitor ISENTRESS® (raltegravir) Tablets in combination therapy in previously untreated (treatment-naïve) adult HIV-1-infected patients.
› Verified 1 days ago
| Entity Name | Hmh Emergency Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659383024 PECOS PAC ID: 7911800826 Enrollment ID: O20040128001215 |
News Archive
Dysfunctional, unloved and seemingly of little use, these poor-cousin relatives of genes have lost their protein-coding abilities. They contain material not essential for an organism's survival and are the "last stop" for removal of genomic waste.
A rapid new diagnostic test developed by Sydney researchers will mean fewer tests and less trauma for cancer patients says Richard Christopherson, who has a Personal Chair in the School of Molecular and Microbial Biosciences in the Faculty of Science.
In an important test of one of the first drugs to target core symptoms of autism, researchers at Mount Sinai School of Medicine are undertaking a pilot clinical trial to evaluate insulin-like growth factor (IGF-1) in children who have SHANK3 deficiency (also known as 22q13 Deletion Syndrome or Phelan-McDermid Syndrome), a known cause of autism spectrum disorder (ASD).
Merck, known as MSD outside the United States and Canada, today announced final results from a Phase II clinical study, extending out to 240 weeks, of its integrase inhibitor ISENTRESS® (raltegravir) Tablets in combination therapy in previously untreated (treatment-naïve) adult HIV-1-infected patients.
› Verified 1 days ago
| Entity Name | Cedars-sinai Medical Center Pharmacy #3 |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639172372 PECOS PAC ID: 0446169114 Enrollment ID: O20040204000886 |
News Archive
Dysfunctional, unloved and seemingly of little use, these poor-cousin relatives of genes have lost their protein-coding abilities. They contain material not essential for an organism's survival and are the "last stop" for removal of genomic waste.
A rapid new diagnostic test developed by Sydney researchers will mean fewer tests and less trauma for cancer patients says Richard Christopherson, who has a Personal Chair in the School of Molecular and Microbial Biosciences in the Faculty of Science.
In an important test of one of the first drugs to target core symptoms of autism, researchers at Mount Sinai School of Medicine are undertaking a pilot clinical trial to evaluate insulin-like growth factor (IGF-1) in children who have SHANK3 deficiency (also known as 22q13 Deletion Syndrome or Phelan-McDermid Syndrome), a known cause of autism spectrum disorder (ASD).
Merck, known as MSD outside the United States and Canada, today announced final results from a Phase II clinical study, extending out to 240 weeks, of its integrase inhibitor ISENTRESS® (raltegravir) Tablets in combination therapy in previously untreated (treatment-naïve) adult HIV-1-infected patients.
› Verified 1 days ago
| Entity Name | Centinela Freeman Emergency Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528333101 PECOS PAC ID: 0042469108 Enrollment ID: O20121004000437 |
News Archive
Dysfunctional, unloved and seemingly of little use, these poor-cousin relatives of genes have lost their protein-coding abilities. They contain material not essential for an organism's survival and are the "last stop" for removal of genomic waste.
A rapid new diagnostic test developed by Sydney researchers will mean fewer tests and less trauma for cancer patients says Richard Christopherson, who has a Personal Chair in the School of Molecular and Microbial Biosciences in the Faculty of Science.
In an important test of one of the first drugs to target core symptoms of autism, researchers at Mount Sinai School of Medicine are undertaking a pilot clinical trial to evaluate insulin-like growth factor (IGF-1) in children who have SHANK3 deficiency (also known as 22q13 Deletion Syndrome or Phelan-McDermid Syndrome), a known cause of autism spectrum disorder (ASD).
Merck, known as MSD outside the United States and Canada, today announced final results from a Phase II clinical study, extending out to 240 weeks, of its integrase inhibitor ISENTRESS® (raltegravir) Tablets in combination therapy in previously untreated (treatment-naïve) adult HIV-1-infected patients.
› Verified 1 days ago
| Entity Name | Telemedicine365, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912525817 PECOS PAC ID: 0648683920 Enrollment ID: O20210105001789 |
News Archive
Dysfunctional, unloved and seemingly of little use, these poor-cousin relatives of genes have lost their protein-coding abilities. They contain material not essential for an organism's survival and are the "last stop" for removal of genomic waste.
A rapid new diagnostic test developed by Sydney researchers will mean fewer tests and less trauma for cancer patients says Richard Christopherson, who has a Personal Chair in the School of Molecular and Microbial Biosciences in the Faculty of Science.
In an important test of one of the first drugs to target core symptoms of autism, researchers at Mount Sinai School of Medicine are undertaking a pilot clinical trial to evaluate insulin-like growth factor (IGF-1) in children who have SHANK3 deficiency (also known as 22q13 Deletion Syndrome or Phelan-McDermid Syndrome), a known cause of autism spectrum disorder (ASD).
Merck, known as MSD outside the United States and Canada, today announced final results from a Phase II clinical study, extending out to 240 weeks, of its integrase inhibitor ISENTRESS® (raltegravir) Tablets in combination therapy in previously untreated (treatment-naïve) adult HIV-1-infected patients.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher Libby, MD 1801 E Katella Ave Apt 3060, Anaheim, CA 92805-6658 Ph: (746) 444-3577 | Dr Christopher Libby, MD 1801 E Katella Ave Apt 3060, Anaheim, CA 92805-6658 Ph: (774) 644-4357 |
News Archive
Dysfunctional, unloved and seemingly of little use, these poor-cousin relatives of genes have lost their protein-coding abilities. They contain material not essential for an organism's survival and are the "last stop" for removal of genomic waste.
A rapid new diagnostic test developed by Sydney researchers will mean fewer tests and less trauma for cancer patients says Richard Christopherson, who has a Personal Chair in the School of Molecular and Microbial Biosciences in the Faculty of Science.
In an important test of one of the first drugs to target core symptoms of autism, researchers at Mount Sinai School of Medicine are undertaking a pilot clinical trial to evaluate insulin-like growth factor (IGF-1) in children who have SHANK3 deficiency (also known as 22q13 Deletion Syndrome or Phelan-McDermid Syndrome), a known cause of autism spectrum disorder (ASD).
Merck, known as MSD outside the United States and Canada, today announced final results from a Phase II clinical study, extending out to 240 weeks, of its integrase inhibitor ISENTRESS® (raltegravir) Tablets in combination therapy in previously untreated (treatment-naïve) adult HIV-1-infected patients.
› Verified 1 days ago
Alan C Osgood, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3033 West Orange Avenue, Anaheim, CA 92804 Phone: 714-827-3000 | |
David A Reid, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3033 W Orange Ave, Anaheim, CA 92804 Phone: 714-827-3000 | |
Emily Wing, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3440 E La Palma Ave, Anaheim, CA 92806 Phone: 833-574-2273 | |
Scott R. Johnson, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 441 N Lakeview Ave, Anaheim, CA 92807 Phone: 888-988-2800 | |
Charles Lu, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3440 E La Palma Ave, Anaheim, CA 92806 Phone: 714-644-2000 | |
Ralph E Conner Iii, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3350 W Ball Rd, Anaheim, CA 92804 Phone: 714-220-4533 Fax: 818-587-2493 | |
Gihan K Wetzel, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1111 W La Palma Ave, Anaheim, CA 92801 Phone: 714-774-1450 |